Meet
Leah Keller
She / Her / Hers
Associate Principal
Leah Keller co-manages and edits the Policy 360 Research Series sits on Avalere’s Marketing Team.
Prior to joining Avalere, Leah conducted policy research and analysis on federal healthcare issues such as Medicaid coverage and payment, commercial insurance coverage and access, healthcare reform, and ACA implementation at the Guttmacher Institute, a thinktank focused on advancing reproductive health and rights. Prior, Leah coordinated data collection, analysis, and publications for George Washington University’s Center for Social Well-Being and Development.
Leah holds an MPH in maternal and child health from George Washington University and a BA in anthropology from St. Mary’s College of Maryland.
Authored Content
Graphic Design USA, a publication for graphic design professionals, recognized Avalere's annual report in its Inhouse Design Awards Competition.
Avalere Policy Edge survey of bipartisan health policy experts suggests that PBM oversight and reform legislation will pass during this Congress.
As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.
Part D redesign and OOP smoothing shift financial liability from beneficiaries to plans, incentivizing utilization and formulary management.
Drug manufacturers can use real-world evidence (RWE) before and after approval to advance product development and adoption.
The first Insight in this series explores timing for Medicare negotiation, inflation rebates, and Part D benefit redesign changes and details to be defined.
The CMS Innovation Center offers policymakers a nimble, non-legislative pathway to experiment with new methods of care delivery, payment, and reimbursement in Medicare and Medicaid.
Health plans and other payers can manage drug expenditures through value-based approaches that tie drug pricing to patient outcomes.
The IRA’s drug price negotiation policies, extended marketplace subsidies, and Part D redesign will impact investors’ current portfolios and investment strategy in the future.
Uncertainty related to the Dobbs ruling could have downstream effects on reproductive healthcare that go beyond abortion.
Avalere Policy Edge survey of bipartisan Congressional and health policy experts suggests the Build Back Better Act (BBBA) will likely pass in 2022.